Risankizumab in real life: preliminary results of efficacy and safety in psoriasis during a 16-week period
Author:
Publisher
Springer Science and Business Media LLC
Subject
Dermatology,General Medicine
Link
http://link.springer.com/content/pdf/10.1007/s00403-021-02200-7.pdf
Reference8 articles.
1. McKeage K, Duggan S (2019) Risankizumab: first global approval. Drugs 79(8):893–900. https://doi.org/10.1007/s40265-019-01136-7
2. Gordon KB, Strober B, Lebwohl M et al (2018) Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet 392(10148):650–661. https://doi.org/10.1016/S0140-6736(18)31713-6
3. Reich K, Gooderham M, Thaçi D et al (2019) Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial published correction appears in Lancet [published correction appears in Lancet. 2019 Jul 16]. Lancet 394(10198):576–586. https://doi.org/10.1016/S0140-6736(19)30952-3
4. Reddy V, Yang EJ, Myers B, Liao W (2020) Clinical evaluation of risankizumab-rzaa in the treatment of plaque psoriasis. J Inflamm Res. 13:53–60. https://doi.org/10.2147/JIR.S215196 (Published 2020 Jan 22)
5. Kulig P, Musiol S, Freiberger SN et al (2016) IL-12 protects from psoriasiform skin inflammation. Nat Commun 7:13466
Cited by 42 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Therapy of moderate-to-severe plaque psoriasis;Meditsinskiy sovet = Medical Council;2024-03-06
2. Efficacy and safety of tildrakizumab in elderly patients: real-world multicenter study (ESTER – study);Journal of Dermatological Treatment;2024-02-27
3. One Dose Risankizumab Effectiveness in Psoriasis: A Real‐Life Multicentre Study;Dermatologic Therapy;2024-01
4. Drug Utilization and Measurement of Medication Adherence: A Real World Study of Psoriasis in Italy;Pharmaceutics;2023-11-21
5. Nail psoriasis and nail lichen planus: Updates on diagnosis and management;Journal of the American Academy of Dermatology;2023-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3